Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecanVAN ERP, Nielka P. H; BAKER, Sharyn D; MING ZHAO et al.Clinical cancer research. 2005, Vol 11, Num 21, pp 7800-7806, issn 1078-0432, 7 p.Article

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumorsFAKIH, Marwan G; PENDYALA, Lakshmi; SMITH, Patrick F et al.Clinical cancer research. 2006, Vol 12, Num 4, pp 1237-1244, issn 1078-0432, 8 p.Article

Delta-24 increases the expression and activity of topoisomerase i and enhances the antiglioma effect of irinotecanGOMEZ-MANZANO, Candelaria; ALONSO, Marta M; FUEYO, Juan et al.Clinical cancer research. 2006, Vol 12, Num 2, pp 556-562, issn 1078-0432, 7 p.Article

Intestinal microflora and digestive toxicity of irinotecan in miceBRANDI, Giovanni; DABARD, Jean; RAIBAUD, Pierre et al.Clinical cancer research. 2006, Vol 12, Num 4, pp 1299-1307, issn 1078-0432, 9 p.Article

Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survivalTOMICIC, Maja T; CHRISTMANN, Markus; KAINA, Bernd et al.Cancer research (Baltimore). 2005, Vol 65, Num 19, pp 8920-8926, issn 0008-5472, 7 p.Article

Evidence of activity of irinotecan in patients with advanced AIDS-related Kaposi's sarcomaVACCHER, Emanuela; DI GENNARO, Giampiero; SIMONELLI, Cecilia et al.AIDS (London). 2005, Vol 19, Num 16, pp 1915-1916, issn 0269-9370, 2 p.Article

Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumorsYAMADA, Yasuhide; TAMURA, Tomohide; MCGOVREN, J. Patrick et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 173-182, issn 0344-5704, 10 p.Article

A study of variable hydration states in topotecan hydrochlorideVOGT, Frederick G; DELL'ORCO, Philip C; DIEDERICH, Ann. M et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 40, Num 5, pp 1080-1088, issn 0731-7085, 9 p.Article

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategyDRUMMOND, Daryl C; NOBLE, Charles O; ZEXIONG GUO et al.Cancer research (Baltimore). 2006, Vol 66, Num 6, pp 3271-3277, issn 0008-5472, 7 p.Article

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer modelsSCHLUEP, Thomas; HWANG, Jungyeong; JIANJUN CHENG et al.Clinical cancer research. 2006, Vol 12, Num 5, pp 1606-1614, issn 1078-0432, 9 p.Article

Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecanCORONA, Giuseppe; VACCHER, Emanuela; CATTAROSSI, Giulio et al.AIDS (London). 2005, Vol 19, Num 17, pp 2043-2044, issn 0269-9370, 2 p.Article

Pharmacokinetics of lactone, carboxylate and total 9-nitro- camptothecin with different doses and administration routes in ratsJUN CHEN; QINENG PING; JIANXIN GUO et al.Biopharmaceutics & drug disposition. 2006, Vol 27, Num 2, pp 53-59, issn 0142-2782, 7 p.Article

Distribution of anticancer drug camptothecin in Nothapodytes foetidaFULZELE, Devanand P; SATDIVE, Ramesh K.Fitoterapia (Milano). 2005, Vol 76, Num 7-8, pp 643-648, issn 0367-326X, 6 p.Article

Liposomalization of SN-38 as active metabolite of CPT-11SADZUKA, Yasuyuki; TAKABE, Hiroyuki; SONOBE, Takashi et al.Journal of controlled release. 2005, Vol 108, Num 2-3, pp 453-459, issn 0168-3659, 7 p.Article

Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in childrenTURNER, P. Kellie; IACONO, Lisa C; PANETTA, John C et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 475-482, issn 0344-5704, 8 p.Article

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patientsJONSSON, E; FRIDBORG, H; NYGREN, P et al.European journal of clinical pharmacology. 1998, Vol 54, Num 7, pp 509-514, issn 0031-6970Article

Dose-finding phase i clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumorsKUPPENS, Isa E. L. M; DANSIN, Eric; BOOT, Henk et al.Clinical cancer research. 2006, Vol 12, Num 12, pp 3774-3781, issn 1078-0432, 8 p.Article

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndromeKANTARJIAN, Hagop; BERAN, Miloslav; CORTES, Jorge et al.Cancer. 2006, Vol 106, Num 5, pp 1099-1109, issn 0008-543X, 11 p.Article

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrheaTAKASUNA, K; HAGIWARA, T; WATANABE, K et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 4, pp 494-503, issn 0344-5704, 10 p.Article

[¹³¹I]meta-lodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporterMCCLUSKEY, Anthony G; BOYD, Marie; ROSS, Susan C et al.Clinical cancer research. 2005, Vol 11, Num 21, pp 7929-7937, issn 1078-0432, 9 p.Article

Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditionsVAN RENSBURG, C. E. J; SLABBERT, J. P; BOHM, L et al.Anticancer research. 2006, Vol 26, Num 1A, pp 389-393, issn 0250-7005, 5 p.Article

Circumvention of camptothecin-induced resistance during the adaptive cellular stress responseTILIGADA, Ekaterini; PAPAMICHAEL, Konstantinos; VOVOU, Ioanna et al.Anticancer research. 2006, Vol 26, Num 1A, pp 421-425, issn 0250-7005, 5 p.Article

Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micellesKAWANO, Kumi; WATANABE, Masato; YAMAMOTO, Tatsuhiro et al.Journal of controlled release. 2006, Vol 112, Num 3, pp 329-332, issn 0168-3659, 4 p.Article

Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing miceSCHLUEP, Thomas; JIANJUN CHENG; KHIN, Kay T et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 5, pp 654-662, issn 0344-5704, 9 p.Article

Gefitinib (Iressa) inhibits the cyp3a4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecanFUJITA, Ken-Ichi; ANDO, Yuichi; NARABAYASHI, Masaru et al.Drug metabolism and disposition. 2005, Vol 33, Num 12, pp 1785-1790, issn 0090-9556, 6 p.Article